A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

The requested reference [d79a8f4e0c9722383c3ad1f1de780d57b3bf961c] no longer exists in our database. It has been replaced by the current reference: [05e637eb8ec52afbd8d45ac5ce1ea81db7d01f23]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who go to the Emergency Department (ED) or their physician\'s office with an acute bronchospasm. Subjects presenting to the ED or physician\'s office with an acute bronchospasm must have a history of reactive airways disease, based on subjects\' parent/guardian report.
Epistemonikos ID: 2052b22c49d2ac32ad214369934586f7a5c8c9d4
First added on: May 11, 2024